FDA Clears Bioequivalence Hurdle for NRx’s Preservative-Free Ketamine
Event summary
- FDA’s Office of Generic Drugs found no bioequivalence deficiencies in NRx’s preservative-free ketamine application, a preliminary step toward ANDA approval.
- NRx anticipates a final FDA decision on its ANDA application in Summer 2026.
- The preservative-free formulation eliminates benzethonium chloride (BZT), a toxic preservative, and aims for three years of room temperature stability.
- NRx’s product is manufactured domestically, aligning with FDA’s focus on resilient U.S. drug supply chains.
The big picture
NRx’s preservative-free ketamine addresses a regulatory and safety gap in the market, potentially modernizing ketamine therapy. The FDA’s focus on domestic drug supply chains adds strategic weight to NRx’s U.S.-manufactured product. If approved, this could set a precedent for other generic drug applications aiming to eliminate toxic preservatives.
What we're watching
- Regulatory Execution
- Whether NRx can secure final FDA approval by Summer 2026, avoiding delays in its ANDA process.
- Market Differentiation
- How NRx positions its preservative-free ketamine as a branded generic, competing with existing formulations.
- Supply Chain Resilience
- The pace at which FDA prioritizes domestic manufacturing of critical drugs like ketamine.
Related topics